The role and efficacy of ozanimod

Touchstone is a double-blind, placebo-controlled Phase II clinical trial of ozanimod in the treatment of ulcerative colitis. Recruited patients will be assigned to the placebo group, 0.5 mg or 1 mg oral ozanimod group, followed by a 1-week dose escalation treatment. The 1 mg dose showed a slight increase in the rate of clinical remission and total lymphopenia in ulcerative colitis compared with placebo, with the most common side effects being headache and anemia.

Radiance is a double-blind, placebo-controlled Phase II/III combination clinical trial for the treatment of relapsing multiple sclerosis. In the phase II trial, enrolled patients were assigned to placebo, 0.5 mg, or 1 mg oral ozanimod, followed by 1 week of dose escalation. Over 24 weeks, ozanimod significantly reduced MRI lesion activity in patients with relapsing multiple sclerosis. Both doses of ozanimod achieved the expected lymphocyte count reduction range of 60-70% and were well tolerated. Its safety profile was consistent with previous phase 1 studies in healthy volunteers. The most common adverse reactions were nasopharyngitis, headache and urinary tract infection, and there were no serious infectious or cardiac adverse reactions.

The original drug Ozamod has been launched in China, but it has been on the market for a short time and has not been included in the medical insurance. The specific price is not yet clear, and domestic purchase channels are relatively difficult. The price of Ozamod original drug specifications0.92*28 capsules per box listed overseas may be around 19,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There is currently no generic version of Ozamod produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.